Integrated personalized cell technologies for improving health outcomes in children and adults

PACT well represented at ISCT Annual Meeting

Several members of PACT’s staff recently attended the 2022 Annual Meeting of the International Society for Cell & Gene Therapy, May 4-7, 2022, in San Francisco, CA. From bench research to cell manufacturing, many aspects of PACT’s pipeline were presented.

Andrea Pennati, Director of Research and Development gave an oral presentation on his abstract, “Manufacture of IL-10+ Regulatory B Cells (Bregs) by Stimulation of Peripheral Blood B Cells with Anti-CD40 Single-Chain Variable Fragment and IL-21 fusion Protein.” Pennati also presented a poster on his second abstract, “Subcutaneous delivery of Allogeneic Interferon-γ Licensed Bone Marrow Derived Mesenchymal Stromal Cell (IFN-γ MSC) for the Treatment of Traumatic Brain Injury (TBI).”

Ross Meyers, Director of Cell Manufacturing, presented at the

Ross Meyers Elevator Pitch Session

Elevator Pitch Session as well as a poster for his abstract, “GMP Process Performance Qualification for the Manufacture and Quality Control Testing of Allogeneic Haploidentical BK Virus-specific T Cells (BK VST),” discussing the quality assurance of one of PACT’s current clinical trials, “A Phase I Study Evaluating Safety and Tolerability of Viral-Specific T cells against BK-Virus in Adult Kidney Transplant Recipients.”

Olga Ganz, cell manufacturing technologist, presented a poster for her abstract, “”IND CMC compatible Purity and Identity Assessment of IFNγ-stimulated Bone Marrow Sourced Mesenchymal Stromal Cells for a Phase I Clinical Trial.”

In addition to moderating several plenary and roundtable sessions, PACT Director Jacques Galipeau was officially inducted as ISCT president for the next two years. Additional information regarding Galipeau’s presidency can be found here.